Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Diacylglycerol kinase (DGK) inhibitors block the conversion of diacylglycerol into phosphatidic acid. Mammals express ten DGK isozymes, which a 2007 review grouped into five types by their regulatory domains. By removing diacylglycerol, the enzymes limit signaling through protein kinase C (PKC) and other diacylglycerol-binding effectors. Mice lacking DGKζ showed enhanced T cell responses in a 2003 study, which linked the isozyme to control of T cell activation. DGKα and DGKζ are therefore studied as negative regulators of T cell receptor signaling. BMS-986408 inhibits both isozymes, while DGKα-IN-2 and DGKζ-IN-6 are directed at single isoforms. R 59-022, offered as base and hydrochloride, is an older DGK inhibitor used in many cell studies.
CU-3 is a selective inhibitor of diacylglycerol kinase alpha (DGKα) with an IC50 of 0.6 μM. By competitively binding to the enzyme's catalytic site, CU-3 decreases DGKα's affinity for ATP, leading to apoptosis in cancer cells. This compound also enhances T-cell activation and increases interleukin-2 (IL-2) production, making it a valuable tool for research in hepatocellular carcinoma and cervical cancer.
Out of stock
All 3 sizes
DGKα-IN-2 is a potent inhibitor of diacylglycerol kinase alpha (DGKα) with an IC50 of 0.9 nM. This compound significantly enhances the anti-tumor efficacy of anti-PD-1 therapy by promoting T cell proliferation and functionality. DGKα-IN-2 serves as a valuable tool in cancer research and immunology studies, offering insights into the modulation of immune responses.
BMS-986408 is a potent inhibitor of diacylglycerol kinases alpha (DGKα) and zeta (DGKζ), exhibiting IC50 values of 0.0003 μM and 0.002 μM respectively. This compound enhances intratumoral T cell responses and promotes the priming and expansion of tumor-reactive T cells in tumor-draining lymph nodes, functioning as a valuable immunostimulant. BMS-986408 is useful for investigating tumor immunology and T cell activation in cancer research.
DGKα-IN-10 is a potent inhibitor of diacylglycerol kinase alpha (DGKα), exhibiting an IC50 of 0.27 nM. This compound has been shown to enhance IL-2 release and promote T cell proliferation, making it valuable for immunological studies. DGKα-IN-10 is suitable for research applications focused on cancer immunotherapy, particularly in the context of colon cancer.
Out of stock
All 3 sizes
DGKα/ζ-IN-2 is a selective dual inhibitor of diacylglycerol kinases α and ζ, exhibiting IC50 values of 23 nM and 1.2 nM, respectively. This compound demonstrates notable selectivity towards DGKα and DGKζ over other isoforms, such as DGKβ and DGKγ. In preclinical studies, DGKα/ζ-IN-2 has been shown to effectively enhance immune activation in the presence of antigen presentation, highlighting its potential for applications in antitumor immunity research.
Out of stock
All 3 sizes
DGKζ-IN-7 is a potent DGKζ inhibitor with an IC50 value of 33.4 nM. This compound effectively inhibits the secretion of IL-2, making it a valuable tool for investigating mechanisms in cancer and autoimmune disease research. Its oral bioavailability adds convenience for in vivo studies, facilitating deeper exploration of DGKζ's role in immune regulation and tumorigenesis.
Out of stock
All 3 sizes
DGKζ-IN-6 is a selective inhibitor of diacylglycerol kinase zeta (DGKζ) with an IC50 of 45.5 nM. This compound effectively inhibits the secretion of interleukin-2 (IL-2), making it relevant for research into cancer and autoimmune diseases. Its ability to modulate IL-2 release positions DGKζ-IN-6 as a valuable tool for investigating the role of DGKζ in immune responses and related therapeutic pathways.
Out of stock
All 3 sizes
Synonyms: DKGI-I; Diacylglycerol kinase inhibitor I
R 59-022 is a selective diacylglycerol kinase (DGK) inhibitor with an IC50 value of 2.8 µM. This compound effectively inhibits the phosphorylation of 1-oleoyl-2-acetylglycerol (OAG) to 1-oleoyl-2-phosphonoacetic acid (OAPA). Additionally, R 59-022 acts as a 5-HT receptor antagonist and activates protein kinase C (PKC). Its ability to potentiate thrombin-induced diacylglycerol production in platelets and inhibit phosphatidic acid production in neutrophils makes it a valuable tool for studying signaling pathways in various cellular contexts.
Synonyms: DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride
R 59-022 hydrochloride is a potent diacylglycerol kinase (DGK) inhibitor, exhibiting an IC50 of 2.8 µM. This compound inhibits the conversion of 1-oleoyl-2-acetylglycerol (OAG) to O-phosphoacylglycerol (OAPA) while also acting as a 5-HT receptor antagonist. Additionally, R 59-022 hydrochloride activates protein kinase C (PKC), enhances thrombin-induced diacylglycerol production in platelets, and suppresses phosphatidic acid synthesis in neutrophils. Its applications include investigations into platelet activation and neutrophil signaling pathways.
DGKα-IN-8 is a selective diacylglycerol kinase alpha (DGKα) inhibitor, exhibiting an IC50 value of 22.491 nM and an EC50 of 0.256 nM. This compound is valuable for research in oncology, particularly in the study of solid tumors, as well as in virology, including investigations into HIV and hepatitis B virus infections. DGKα-IN-8 provides a tool for elucidating the role of DGKα in various cellular processes and disease mechanisms.
Out of stock
All 3 sizes
Synonyms: BAY 2965501
Veludacigib is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. It effectively induces phosphorylation of extracellular signal-regulated kinase (pERK), promoting downstream signaling pathways. This compound is valuable in cancer research, offering insights into the role of DGKζ in tumorigenesis and potential therapeutic strategies.
BMS-502 is a potent dual inhibitor of diacylglycerol kinases (DGK) α and ζ, exhibiting IC50 values of 4.6 nM and 2.1 nM, respectively. This compound has been shown to enhance T cell immune responses in murine models, making it a valuable tool for investigating tumor immunity. BMS-502 is suitable for research applications focused on immune modulation and cancer biology.
BMS-684 is a selective diacylglycerol kinase alpha (DGKα) inhibitor, exhibiting an IC50 of 15 nM. This compound demonstrates over 100-fold selectivity for DGKα compared to other DGK type I family members, specifically DGKβ and DGKγ, while sparing the remaining seven DGK isozymes. BMS-684 is valuable in research applications exploring signal transduction pathways and lipid metabolism involving DGKα modulation.
(1R)-BMS-986408 is an orally active dual inhibitor of diacylglycerol kinases (DGK) α and ζ. This compound enhances T cell signaling, thereby restoring T cell-mediated anti-tumor immunity. It serves as a valuable tool for research into cancer immunotherapy and the modulation of immune responses.
DGK-IN-10 is a potent diacylglycerol kinase (DGK) inhibitor, demonstrating IC50 values of ≤ 10 nM against both DGKα and DGKζ isoforms. This compound exhibits significant inhibitory activity, making it a valuable tool in research related to various diseases, including cancer. Its specificity for DGK isoforms allows for detailed investigations into the role of DGK in cellular signaling pathways and disease mechanisms.
Out of stock
All 3 sizes
Synonyms: Ethylene glycol dicaprylate; Ethylene glycol dioctanoate; Ethylenedioctanoate
Dioctanoylglycol is a diacylglycerol (DG) analog that serves as a potent inhibitor of diacylglycerol kinase (DGK), with a Ki value of 58 μM. This compound is utilized in research to study the role of DGK in signal transduction pathways and its implications in various cellular processes. Its ability to modulate DGK activity makes it a valuable tool for understanding DGK-related signaling mechanisms and exploring potential therapeutic avenues.
BMS-332 is a potent dual inhibitor of diacylglycerol kinases α and ζ, exhibiting IC50 values of 5 nM and 1 nM, respectively. This compound enhances antigen-specific T cell responses and effectively reduces viral load in the liver and spleen when paired with anti-PD-1 therapies in chronic infection models. BMS-332 is a valuable tool for investigating T cell immune checkpoint strategies in immunology and related research fields.
DGK-IN-1 is an inhibitor of diacylglycerol kinase (DGK) isoforms DGKa and DGKz, with IC50 values of 0.65 µM and 0.25 µM, respectively. This compound serves as a potent T cell activator, making it valuable for studies related to cancer immunology and viral infections. By modulating T cell activity, DGK-IN-1 can aid in understanding immune responses and therapeutic strategies in various disease contexts.
AMB639752 is a selective inhibitor of diacylglycerol kinase alpha (DGKα). This reagent effectively restores restimulation induced cell death (RICD) in SAP-deficient lymphocytes by targeting DGKα in intact cellular systems. AMB639752 is suitable for investigations related to X-linked lymphoproliferative disease type 1 (XLP-1) and provides a valuable tool for studying lymphocyte signaling and apoptosis.
DGKζ-IN-4 is a selective diacylglycerol kinase zeta (DGKζ) inhibitor. This compound has demonstrated significant biological activity in modulating immune cell activation, making it a valuable tool for cancer research. It is particularly relevant for investigating cancers associated with immune evasion, including those resistant to anti-PD-1 and anti-PD-L1 antibody therapies. DGKζ-IN-4 can serve as an active component in pharmaceutical compositions aimed at enhancing antitumor immunity.
Synonyms: DGKζ-IN-1
Alcudacigib is a selective inhibitor of diacylglycerol kinase zeta (DGKζ), targeting key signaling pathways involved in cellular activation. This compound exhibits significant biological activity in the modulation of immune responses, making it a valuable tool for research related to cancer immunotherapy and mechanisms of resistance to anti-PD-1 or anti-PD-L1 antibody therapies. Researchers can utilize Alcudacigib to explore its effects on immunocyte activation in cancer models.
Out of stock
All 3 sizes
BMS-496 is a selective inhibitor of diacylglycerol kinase alpha (DGKα) and zeta (DGKζ), exhibiting IC50 values of 0.09 μM and 0.006 μM, respectively. This compound is crucial for studying the role of DGK isoforms in various cellular processes, including receptor signaling and lipid metabolism. BMS-496 is valuable for researching therapeutic strategies targeting DGK-related pathways in cancer, inflammation, and other diseases.
Pasodacigib is a selective inhibitor of diacylglycerol kinase alpha (DGKα). This compound is utilized in research to investigate the role of DGKα in various cellular processes, including signal transduction and lipid metabolism. Its inhibition of DGKα has potential implications for studying cancer, inflammation, and neurodegenerative diseases.
DGK-IN-11 is a potent diacylglycerol kinase (DGK) inhibitor, specifically targeting DGKα and DGKγ. This compound effectively modulates intracellular diacylglycerol levels, leading to enhanced T cell activation, increased cytokine production, and improved cell proliferation. DGK-IN-11 is a valuable tool for investigating its potential applications in cancer research.
Out of stock
All 3 sizes
DGKα-IN-9 is a specific inhibitor of diacylglycerol kinase alpha (DGKα). It has been shown to inhibit tumor growth in mouse models such as MC38 and CT26. This compound is valuable for research applications focused on cancer biology and therapeutic development.
Out of stock
All 3 sizes